Crinetics Pharmaceuticals, Inc. · NASDAQ:CRNX
Crinetics Pharmaceuticals — Q3 2025 Earnings Presentation
24 slides from Crinetics Pharmaceuticals's earnings presentation, Nov 6, 2025
Slide 1: Third Quarter 2025 Financial Results and Business Update
November 6, 2025 Third Quarter 2025 Financial Results and Business Update
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements. Crinetics Pharmaceuticals, Inc. (“Crinetics,” the “company,” “we,” “us,” or “our”) cautions you that all statements other than statements of historical facts contained in this presentation are forward-looking statement
Slide 3: Introductory Remarks
INTRODUCTORY REMARKS Scott Struthers Founder & Chief Executive Officer CRINETICS PHARMACEUTICALS | 3
Slide 4: PALSONIFY: A New Era in Acromegaly Treatment
PALSONIFY: A New Era in Acromegaly Treatment Broad Label with Strong Clinical Data on Biochemical and Symptom Control Sets the Foundation for a Strong Commercial Launch of PALSONIFY CRINETICS PHARMACEUTICALS | 4
Slide 5: Our Mission
Our Mission: To be the world’s leading endocrine company that consistently pioneers new therapeutics to help patients better control their disease and improve their daily lives Acromegaly Carcinoid Syndrome Congenital Adrenal Hyperplasia ACTH-Dependent Cushing’s Syndrome Tony Ellen Wendy NETs and SS
Slide 6: Palsonify Launch: Early Momentum and Upcoming Key Metrics
Palsonify Launch: Early Momentum and Upcoming Key Metrics Strong Start of Palsonify Launch What We Will Share in January Palsonify Revenue* Patients transitioning from OLE Prescribers from PTC and New Patient Starts community settings with stronger than expected engagement from community Number of P
Slide 7: Three-Phase Strategy for Helping More People with Acromegaly Get the Care They Need
Three-Phase Strategy for Helping More People with Acromegaly Get the Care They Need Switch & Naive Return to Care Diagnose 36,000 17,000 Undiagnosed 19,000 No Active 7,500 Follow-up 10,000 Recent Treatment 1,500 Discontinued 4,500 Treatment Naive 3,000 Injectable SRL 2,500 Other Therapies Phase 1 Ph
Slide 8: Continued Value Creation with Deep Pipeline of Transformative Drug Candidates
Continued Value Creation with Deep Pipeline of Transformative Drug Candidates Program Preclinical Phase 1 Phase 2 Phase 3 Registration Upcoming Milestones Acromegaly (US) PDUFA Date Approved (September September 2025) 25, 2025 Paltusotine (SST2 agonist) Acromegaly (EU) CHMP Opinion (1H 2026) Carcino
Slide 9: Carcinoid Syndrome: CAREFNDR Phase 3 for Paltusotine
Carcinoid Syndrome: CAREFNDR Phase 3 for Paltusotine Trial Size: 141 patients, 2:1 randomization Key Eligibility Criteria: • Treatment naïve or currently untreated and actively symptomatic –OR- controlled on SRL therapy and symptom worsening upon washing out of treatment • Grade 1 or 2 NET, Positive
Slide 10: NETs & SST2+ Tumors: CRN09682 Phase 1/2 Study
NETs & SST2+ Tumors: CRN09682 Phase 1/2 Study Will Be Proof of Concept for NDC Platform Ph 1: Dose Escalation Ph 2: Dose Expansion* • Bayesian Optimal Interval design, n=3-6/cohort • n=approximately 25/cohort MTD Cohort 1: Pancreatic NET Key Eligibility Criteria: Well-differentiated • Metastatic or
Slide 11: Adult CAH: Design and Status, Phase 2 Atumelnant
Adult CAH: Design and Status, Phase 2 Atumelnant Treatment Arms: Key Eligibility Criteria • 4 cohorts, each 12 weeks (N=6-12) N=34-40 • Male or female 40 mg Once Daily (PM Dosing) (n=11) participants ≥18 to 75 years. Age: ≥16 years (US) 80 mg Once Daily (PM Dosing) (n=11) • Classic 21-hydroxylase de
Slide 12: Adult CAH: Global Phase 3 Trial Designed to Assess Normalization of Androgen and Glucocorticoids
Adult CAH: Global Phase 3 Trial Designed to Assess Normalization of Androgen and Glucocorticoids Key Eligibility Criteria (N = 150): • Male or female participants ≥ 18 to 75 years. • A4 > ULN1 with supraphysiologic GC dose (≥11 mg/m2/day) • Classic 21-hydroxylase deficiency • A4 > ULN1 with physiolo
Slide 13: Pediatric CAH: Global Phase 2/3/OLE Operationally Seamless Trial
Pediatric CAH: Global Phase 2/3/OLE Operationally Seamless Trial Phase 2 (Part A) – GC Stable Phase 3 (Part B) – GC Reduction OLE (Part C) – GC Reduction N=24-48 N=105 N=153 EOT EOS EOT EOS Dose Selection (8 weeks) Part A Dose Decisions Randomized, Double-Blind Triggers Enrollment for Part B Screeni
Slide 14: Commercial Update
COMMERCIAL UPDATE Isabel Kalofonos Chief Commercial Officer CRINETICS PHARMACEUTICALS | 14
Slide 15: Executing on Our Strategy to Make PALSONIFY the Foundation of Acromegaly Care
Executing on Our Strategy to Make PALSONIFY the Foundation of Acromegaly Care Leverage synergistic field teams and targeted marketing to educate on best-in-class profile and streamline access PATIENTS PROVIDERS PAYERS Activate patients Make PALSONIFY the Demonstrate value to start, switch, or therap
Slide 16: Activating Both Naïve and Switch Patients
Activating Both Naïve and Switch Patients Reinforcing IGF-1 and Symptom Control in a Once-Daily Oral PATIENTS Activate patients to start, PATIENT ACTIVATION switch, or resume treatment ACROMEGALY REALITY All 22 Disease education campaign to raise awareness of the lived realities of acromegaly and su
Slide 17: Leading with Efficacy First to Engage Providers
Leading with Efficacy First to Engage Providers Key messages that have resonated among PROVIDERS active prescribers: Make PALSONIFY the therapy of choice Strong efficacy data in both switch and naïve patients IGF-1 normalization and symptom improvement 95% Top prescriber Ease of administration with
Slide 18: Positive Initial Response from Payers: Rapid Access
Positive Initial Response from Payers: Rapid Access Strong value proposition to payers – expect formulary coverage in most plans within 6-9 months PAYERS Demonstrate value proposition Unprecedented Safety and Maintain Control to facilitate access Efficacy Limit patient and societal Ability to achiev
Slide 19: Financial Update
FINANCIAL UPDATE Toby Schilke Chief Financial Officer CRINETICS PHARMACEUTICALS | 19
Slide 20: Financial Results
Financial Results Three Months Ended (in millions) September 30, 2025 June 30, 2025 Revenues $ 0.1 $ 1.0 R&D Expenses (90.5) (80.3) SG&A Expenses (52.3) (49.8) Net Loss $ (130.1) $ (115.6) October 28, 2025 Common Stock Outstanding 94.9 Million Fully Diluted Share Count* 111.9 Million CRINETICS P
Slide 21: $1.1 Billion Cash Balance Funds Current Operating Plan into 2029
$1.1 Billion Cash Balance Funds Current Operating Plan into 2029 CRN09682 $1.1 Billion Progressive Disease Supports Strategic Initiatives Including: Cash, cash equivalents, & investments as of September 30, 2025 ➢ Commercialization of PALSONIFY ➢ Pipeline programs and innovation from Into 2029 disco
Slide 22: Closing Remarks
CLOSING REMARKS Scott Struthers Founder & Chief Executive Officer CRINETICS PHARMACEUTICALS | 22
Slide 23: Poised to Deliver Multiple Commercial & Clinical Catalysts in the Next 24+ Months
Poised to Deliver Multiple Commercial & Clinical Catalysts in the Next 24+ Months TODAY Commercial U.S. FDA Catalysts: U.S. Launch Trajectory Approval Clinical TOUCAHN Balance-CAH (Peds) Calm-CAH (Adult) Catalysts: Cohort 1-3 Readout Cohort 4 + OLE Readout Phase 2 Preliminary Data Phase 3 Readout AD
Slide 24: Q&A Session
Q&A Session SCOTT STRUTHERS STEPHEN BETZ ISABEL KALOFONOS Founder and Founder and Chief Commercial Officer Chief Executive Officer Chief Scientific Officer TOBY SCHILKE DANA PIZZUTI ALAN KRASNER Chief Financial Officer Chief Medical Officer Chief Endocrinologist CRINETICS PHARMACEUTICALS | 24
Crinetics Pharmaceuticals — Q3 2025 Earnings Presentation on 6ix